- Home
- VTLE vs CSTL Comparison
VTLE vs CSTL Comparison
Compare VTLE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- CSTL
- Stock Information
- Founded
- VTLE 2006
- CSTL 2007
- Country
- VTLE United States
- CSTL United States
- Employees
- VTLE N/A
- CSTL N/A
- Industry
- VTLE
- CSTL Medical Specialities
- Sector
- VTLE
- CSTL Health Care
- Exchange
- VTLE Nasdaq
- CSTL Nasdaq
- Market Cap
- VTLE 592.9M
- CSTL 555.8M
- IPO Year
- VTLE 2011
- CSTL 2019
- Fundamental
- Price
- VTLE $16.42
- CSTL $23.56
- Analyst Decision
- VTLE Hold
- CSTL Strong Buy
- Analyst Count
- VTLE 11
- CSTL 6
- Target Price
- VTLE $25.67
- CSTL $37.67
- AVG Volume (30 Days)
- VTLE 2.2M
- CSTL 599.5K
- Earning Date
- VTLE 11-05-2025
- CSTL 11-03-2025
- Dividend Yield
- VTLE N/A
- CSTL N/A
- EPS Growth
- VTLE N/A
- CSTL N/A
- EPS
- VTLE N/A
- CSTL N/A
- Revenue
- VTLE $1,935,411,000.00
- CSTL $346,269,000.00
- Revenue This Year
- VTLE $2.60
- CSTL N/A
- Revenue Next Year
- VTLE N/A
- CSTL N/A
- P/E Ratio
- VTLE N/A
- CSTL N/A
- Revenue Growth
- VTLE 5.26
- CSTL 20.40
- 52 Week Low
- VTLE $12.30
- CSTL $14.59
- 52 Week High
- VTLE $36.72
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- VTLE 47.85
- CSTL 68.31
- Support Level
- VTLE $16.70
- CSTL $22.54
- Resistance Level
- VTLE $18.59
- CSTL $24.51
- Average True Range (ATR)
- VTLE 1.14
- CSTL 1.00
- MACD
- VTLE 0.18
- CSTL 0.23
- Stochastic Oscillator
- VTLE 52.36
- CSTL 82.01
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.